NorthWest Biotherapeutics Inc (NWBO)

[meirluc]

Flipper and GermanCol, wouldn't the trial be facing an ethical dilemma if to fulfill the needs of the trial, a large number of methylated GBM patients and a small number of unmethylated GBM patients were purposely prevented from crossing over?
A roughly equal proportion of methylated and unmethylated GBM patients crossing over would be interpreted as fulfilling the expectation of the trial to give every progressing patient the opportunity to cross over and failure to do so would most likely have been based as an example on a rapid clinical deterioration.
I am sure that every attempt was made to save or at least prolong every patient's life.
To purposely withhold the opportunity of many methylated GBM patients, fewer unmethylated GBM patients or any GBM patient to cross over, seems highly unethical and therefore unlikely to have been carried out. IMHO